IPHA Quote, Financials, Valuation and Earnings

DBV Technologies SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat DBV Technologies SA's return on equity of --.

Innate Pharma SA has a consensus price target of $7.86, signalling upside risk potential of 257.12%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 67.52%. Given that Innate Pharma SA has higher upside potential than DBV Technologies SA, analysts believe Innate Pharma SA is more attractive than DBV Technologies SA.

Innate Pharma SA has a beta of 0.197, which suggesting that the stock is 80.329% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Innate Pharma SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 13.17x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Genfit SA's return on equity of --.

Innate Pharma SA has a consensus price target of $7.86, signalling upside risk potential of 257.12%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 98.46%. Given that Innate Pharma SA has higher upside potential than Genfit SA, analysts believe Innate Pharma SA is more attractive than Genfit SA.

Innate Pharma SA has a beta of 0.197, which suggesting that the stock is 80.329% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Genfit SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 13.17x versus 3.04x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

Inventiva SA has a net margin of -- compared to Innate Pharma SA's net margin of --. Innate Pharma SA's return on equity of -72.79% beat Inventiva SA's return on equity of --.

Innate Pharma SA has a consensus price target of $7.86, signalling upside risk potential of 257.12%. On the other hand Inventiva SA has an analysts' consensus of $10.88 which suggests that it could grow by 221.04%. Given that Innate Pharma SA has higher upside potential than Inventiva SA, analysts believe Innate Pharma SA is more attractive than Inventiva SA.

Innate Pharma SA has a beta of 0.197, which suggesting that the stock is 80.329% less volatile than S&P 500. In comparison Inventiva SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Innate Pharma SA pays -- of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend.

Innate Pharma SA quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Innate Pharma SA's net income of -- is lower than Inventiva SA's net income of --. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 13.17x versus 20.67x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi SA has a net margin of -- compared to Innate Pharma SA's net margin of 17.65%. Innate Pharma SA's return on equity of -72.79% beat Sanofi SA's return on equity of 8.47%.

Innate Pharma SA has a consensus price target of $7.86, signalling upside risk potential of 257.12%. On the other hand Sanofi SA has an analysts' consensus of $65.53 which suggests that it could grow by 25.17%. Given that Innate Pharma SA has higher upside potential than Sanofi SA, analysts believe Innate Pharma SA is more attractive than Sanofi SA.

Innate Pharma SA has a beta of 0.197, which suggesting that the stock is 80.329% less volatile than S&P 500. In comparison Sanofi SA has a beta of 0.546, suggesting its less volatile than the S&P 500 by 45.374%.

Innate Pharma SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi SA offers a yield of 4.23% to investors and pays a quarterly dividend of $2.21 per share. Innate Pharma SA pays -- of its earnings as a dividend. Sanofi SA pays out 84.6% of its earnings as a dividend. Sanofi SA's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Innate Pharma SA quarterly revenues are --, which are smaller than Sanofi SA quarterly revenues of $11.2B. Innate Pharma SA's net income of -- is lower than Sanofi SA's net income of $2B. Notably, Innate Pharma SA's price-to-earnings ratio is -- while Sanofi SA's PE ratio is 18.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innate Pharma SA is 13.17x versus 2.69x for Sanofi SA. Usually stocks with elevated PS ratios are considered overvalued.